While rodents are the primary models for contrast agent evaluation, there is considerable variability in pharmacokinetics of contrast agents in mice vs humans. OATPs play a role in in vivo pharmacokinetics in mice and humans. This study provides evidence that the OATP1B1/1B3 knock-in mouse is a more useful screening tool for novel MRI contrast agents destined for clinical use as compared to the traditionally used wild-type models.
This abstract and the presentation materials are available to members only; a login is required.